NCT00233558View on ClinicalTrials.gov

Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis

PHASE4TerminatedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

June 30, 2005

Conditions
Rheumatoid Arthritis
Interventions
DRUG

adalimumab (up to 9 months exposure)

DRUG

methotrexate

Trial Locations (1)

60064

Global Medical Information - Abbott, North Chicago

Sponsors

Lead Sponsor

Abbott
All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00233558 - Open-Label Steroid Reduction Study of Adalimumab With Methotrexate in Patients With Active Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter